

Shanu Modi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/683008/publications.pdf>

Version: 2024-02-01

92
papers

10,272
citations

53794

45
h-index

46799

89
g-index

92
all docs

92
docs citations

92
times ranked

10150
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	27.0	1,143
2	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	27.0	854
3	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
4	Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2698-2704.	1.6	535
5	Unlocking the potential of antibody-drug conjugates for cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 327-344.	27.6	498
6	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1887-1896.	1.6	465
7	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. <i>Clinical Cancer Research</i> , 2011, 17, 5132-5139.	7.0	396
8	Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 742-755.	4.1	384
9	Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER2-Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 5410-5417.	1.6	333
10	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. <i>Journal of Clinical Oncology</i> , 2012, 30, 3234-3241.	1.6	319
11	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2078-2099.	1.6	303
12	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 816-826.	10.7	252
13	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401.	27.8	233
14	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	9.4	222
15	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 6784-6791.	7.0	176
16	Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. <i>Cancer</i> , 2005, 104, 1575-1579.	4.1	167
17	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	1.6	165
18	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 827-836.	10.7	154

#	ARTICLE	IF	CITATIONS
19	Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opinion on Investigational Drugs, 2014, 23, 611-628.	4.1	146
20	Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2001, 3, 49-57.	2.6	145
21	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2736-2740.	1.6	141
22	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. Ca-A Cancer Journal for Clinicians, 2022, 72, 165-182.	329.8	132
23	Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Research, 2021, 23, 84.	5.0	108
24	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
25	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2804-2807.	1.6	93
26	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 154-160.	2.4	91
27	A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer, 2012, 118, 5733-5740.	4.1	88
28	Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opinion on Drug Discovery, 2011, 6, 559-587.	5.0	87
29	A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer. Clinical Breast Cancer, 2006, 7, 270-277.	2.4	86
30	A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2005, 90, 157-163.	2.5	84
31	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2015, 33, 442-447.	1.6	75
32	Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. JAMA Dermatology, 2018, 154, 670.	4.1	71
33	HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance. Advances in Pharmacology, 2012, 65, 471-517.	2.0	69
34	Pilot study of ⁶⁸ Ga-DOTA-F(ab ²) ₂ -trastuzumab in patients with breast cancer. Nuclear Medicine Communications, 2013, 34, 1157-1165.	1.1	68
35	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. JAMA Oncology, 2021, 7, 1873.	7.1	66
36	Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. Cancer Prevention Research, 2013, 6, 428-436.	1.5	65

#	ARTICLE	IF	CITATIONS
37	Ganetespi: research and clinical development. <i>OncoTargets and Therapy</i> , 2015, 8, 1849.	2.0	62
38	Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 691-703.	2.0	61
39	A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 107-113.	2.5	61
40	Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. <i>Discovery Medicine</i> , 2016, 21, 65-74.	0.5	59
41	A Phase I Dose-Escalation Trial of Trastuzumab and Alveespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 5090-5098.	7.0	58
42	The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target. <i>Current Cancer Drug Targets</i> , 2008, 8, 522-535.	1.6	50
43	A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. <i>Annals of Oncology</i> , 2011, 22, 2575-2581.	1.2	49
44	A Phase II Trial of Gemcitabine in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline and Taxane. <i>Clinical Breast Cancer</i> , 2005, 6, 55-60.	2.4	48
45	Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. <i>JAMA Dermatology</i> , 2019, 155, 724.	4.1	46
46	A phase I trial of ganetespi in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 89.	5.0	45
47	HER2 breast cancer therapies: a review. <i>Biologics: Targets and Therapy</i> , 2009, 3, 289-301.	3.2	45
48	The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. <i>Annals of Surgical Oncology</i> , 2015, 22, 495-501.	1.5	44
49	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 559-573.e7.	16.8	40
50	Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer. <i>Cancer Investigation</i> , 2005, 23, 483-487.	1.3	37
51	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 387-394.	2.4	37
52	Chaperome heterogeneity and its implications for cancer study and treatment. <i>Journal of Biological Chemistry</i> , 2019, 294, 2162-2179.	3.4	37
53	Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry. <i>Electrophoresis</i> , 2001, 22, 2730-2736.	2.4	35
54	Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 34.	5.0	34

#	ARTICLE	IF	CITATIONS
55	Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2020, 26, 5609-5620.	7.0	32
56	Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. <i>Cell Reports</i> , 2020, 31, 107840.	6.4	32
57	Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3665-3673.	1.6	28
58	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin+ Cyclophosphamide (AC) Followed by Nanoparticle Albumin+ Bound Paclitaxel in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3398-3407.	7.0	28
59	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. <i>Oncologist</i> , 2017, 22, 139-143.	3.7	27
60	An update on epidermal growth factor receptor inhibitors. <i>Current Oncology Reports</i> , 2002, 4, 47-55.	4.0	26
61	HER2 breast cancer therapies: a review. <i>Biologics: Targets and Therapy</i> , 2009, , 289.	3.2	25
62	Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 451-456.	2.5	25
63	Dermatologic adverse events related to the PI3K± inhibitor alpelisib (BYL719) in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 227-237.	2.5	22
64	Copper-64 trastuzumab PET imaging: a reproducibility study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 191-198.	0.7	21
65	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5178-5187.	7.0	18
66	Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study. <i>Future Oncology</i> , 2021, 17, 3415-3423.	2.4	17
67	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i> -Mutated HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3867-3875.	7.0	15
68	Preoperative Chemotherapy for Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2665.	7.4	13
69	Measuring Tumor Epichaperome Expression Using [¹²⁴ I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1414-1424.	3.0	13
70	Beyond HER2: Targeting the ErbB receptor family in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 109, 102436.	7.7	13
71	Single-Agent Gemcitabine in the Treatment of Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 4, S101-S106.	2.4	12
72	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. <i>Clinical Breast Cancer</i> , 2016, 16, 276-283.	2.4	11

#	ARTICLE	IF	CITATIONS
73	Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. <i>Cancer Research</i> , 2021, 81, CT167-CT167.	0.9	11
74	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2 ⁺ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428.	7.0	11
75	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
76	Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results. <i>Clinical Breast Cancer</i> , 2010, 10, 33-39.	2.4	8
77	Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics. <i>Journal of Visualized Experiments</i> , 2014, , e52157.	0.3	8
78	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2 ⁺ Positive Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2019, 2, e1916211.	5.9	7
79	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5588-5597.	7.0	7
80	Phase I trial of the HSP-90 inhibitor PU-H71.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2537-2537.	1.6	7
81	Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates. <i>Cornea</i> , 2022, 41, 792-801.	1.7	6
82	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. <i>Oncologist</i> , 2019, 24, e646-e652.	3.7	5
83	Using 124I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11076-11076.	1.6	5
84	The cancer patient with chronic pain due to herpes zoster. <i>Current Review of Pain</i> , 2000, 4, 429-436.	0.7	4
85	Combination versus sequential single-agent therapy for the treatment of metastatic breast cancer. <i>European Journal of Cancer</i> , Supplement, 2005, 3, 3-8.	2.2	4
86	Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. <i>CNS Oncology</i> , 2022, 11, .	3.0	4
87	Targeted Therapy for Human Epidermal Growth Factor Receptor 2 ⁺ Positive Breast Cancer: Can There Be Too Many Active Drugs?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3111-3113.	1.6	3
88	Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10618-10618.	1.6	3
89	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 87-94.	2.4	1
90	Targeting HER2/3 in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 61-69.	1.0	0

#	ARTICLE	IF	CITATIONS
91	Triplet Combination of Endocrine Therapy with CDK 4/6 Inhibitor, Ribociclib, and MTOR Inhibitor, Everolimus in HR+, HER2-ABC: Results from the Dose-Expansion Cohort. <i>Breast</i> , 2017, 36, S46-S47.	2.2	0
92	Reply to T.J.A. Dekker. <i>Journal of Clinical Oncology</i> , 2020, 38, 3351-3352.	1.6	0